Invesco NASDAQ 100 ETF vs Zoetis Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 3.8× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 54 Days and Zoetis Inc for 70 Days on average.
| QQQM | ZTS | |
|---|---|---|
Market Cap | $113.40B | $30.20B |
Volume | 2,866,236 | 6,175,327 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $147.53 |
52-Week Low | $229.87 | $69.09 |
Typical Hold Time | 54 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $309.39, down 0.84% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026 (SEC filing, September 28, 2026).
The outlook remains positive given the Nasdaq-100's exposure to technology growth stocks, though concentration risk in top holdings and potential tax complications with covered-call alternatives like QQQI warrant caution. Market leadership from small-cap stocks within the index suggests continued momentum, but investors should monitor valuation levels given the current price near resistance at $311.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →